Paige Young
Primary Care · Conway, SCNPI 1982305843
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,932 and has fallen 64.8% since, to $679 in 2025.
Across 171 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$469
- Novo Nordisk$413
- AbbVie$397
- Lilly USA, LLC$250
- AstraZeneca$208
- Ironwood Pharmaceuticals, Inc$205
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,19895%
- Education$1515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 24 | $469 |
| Novo Nordisk | 17 | $413 |
| AbbVie | 29 | $397 |
| Lilly USA, LLC | 11 | $250 |
| AstraZeneca | 13 | $208 |
| Ironwood Pharmaceuticals, Inc | 12 | $205 |
| Astellas Pharma US Inc | 4 | $189 |
| Bayer | 6 | $167 |
| Pfizer | 9 | $157 |
| Phathom Pharmaceuticals, Inc. | 2 | $106 |
| Esperion Therapeutics, Inc. | 6 | $103 |
| Exact Sciences | 5 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Amgen | 4 | $60 |
| Sumitomo Pharma America, Inc. | 2 | $54 |
| Mylan Specialty L.p. | 2 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Ardelyx, Inc. | 2 | $40 |
| Nevro Corp. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Merck | 1 | $22 |
| Viatris Specialty LLC | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Sonex Health, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,349 in reported general payments places this provider in the 85th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $58,721 |
| JanuviaSitagliptin Phosphate | 27 | $30,397 |
| RybelsusSemaglutide | 19 | $26,746 |
| MounjaroTirzepatide | 25 | $26,346 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $20,476 |
| JardianceEmpagliflozin | 14 | $12,638 |
| EliquisApixaban | 15 | $11,757 |
| FarxigaDapagliflozin Propanediol | 13 | $9,529 |
| MyrbetriqMirabegron | 13 | $6,759 |
| Omeprazole | 95 | $1,832 |
| Rosuvastatin Calcium | 88 | $1,594 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,483 |
| Sucralfate | 14 | $1,299 |
| Pantoprazole Sodium | 80 | $1,015 |
| Famotidine | 58 | $958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $413 | $85,46876 claims |
| MerckJanuvia | $22 | $30,39727 claims |
| Lilly USA, LLCMounjaro | $250 | $26,34625 claims |
| GSKTrelegy Ellipta | $469 | $20,47625 claims |
| Boehringer IngelheimJardiance | $19 | $12,63814 claims |
| PfizerEliquis | $157 | $11,75715 claims |
| AstraZenecaFarxiga | $208 | $9,52913 claims |
| Astellas Pharma US IncMyrbetriq | $189 | $6,75913 claims |
| AbbVieSynthroid | $397 | $91321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 115 primary care providers in South Carolina.
Other primary care in Conway
- Sarah TomashefskiGreenville$23K
- Samantha VaughtNorth Myrtle Beach$15K
- Cynthia SmithSeneca$10K
- William ByrdSumter$10K
- Kathleen BoonePawleys Island$9K
- Amanda GroomeGreenville$9K
- Holly SurrencyAiken$8K
- Jessica BoldenAnderson$8K
- Caren ArnetteDillon$7K
- Heather MartinSeneca$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.